02/12/2019

Fidia Introduces in the US the 3-injection regimen TRILURON (sodium hyaluronate)

Fidia's wholly owned subsidiary, Fidia Pharma USA Inc., introduces in the US, TRILURON™ , a Hyaluronic Acid (HA) based intra-articular viscosupplement indicated for the
treatment of pain in osteoarthritis of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and to simple analgesics (e.g., acetaminophen).

TRILURON™ treatment cycle

TRILURON™ treatment cycle consists of 3 injections given at weekly intervals. The launch of the 3-injection product, TRILURON™, represents an important new, convenient treatment option for physicians and their patients. It also completes the HA viscosupplement portfolio offering for Fidia Pharma USA Inc. building on the successes of Hymovis®, the only 2-injection HA-based hydrogel viscosupplement and the flagship Hyalgan®, a 5-injection regimen and the first HA product approved for treatment of knee OA pain in the United States.

A full range of products for musculoskeletal care

With a full range of HA-viscosupplement products available, Fidia Pharma USA is uniquely positioned to provide proven solutions for a broad range of patients with pain associated with osteoarthritis (OA) of the knee. Additional products available from Fidia Pharma USA, NuDYN TM , an acellular injectable, flowable, shelf-stable, amniotic membrane allograft and CartiJoint TM FORTE dietary supplement, enhance the robust and growing portfolio of quality non-surgical solutions being made available to physicians providing orthopaedic and musculoskeletal care to their patients.

Health
Products
Website

Find out more about Fidia’s product portfolio:

Go to the website

Key Business Areas

Fidia operates in numerous therapeutic areas, providing specific, innovative treatments for commonly occurring pathologies with major socio-economic impact, namely:

- joint healthcare
- ophthalmology
- wound care
- dermatology
- neurology
- dermo-aesthetics